by Symmetron | Jan 18, 2019
atrial fibrillation Economic evaluation of insertable cardiac monitors to detect atrial fibrillation and subsequently moderate stroke risk in a high-risk population in the UK Presented at ISPOR Europe. November 10-14, 2018. Barcelona, Spain. Authors C. Rinciog, L....
by Symmetron | Jan 18, 2019
Idiopathic Pulmonary Fibrosis Pharmacoeconomic Assessment of Nintedanib For The Treatment of Idiopathic Pulmonary Fibrosis In The Greek Healthcare System Presented at ISPOR Europe. October 29 to November 2, 2016. Vienna, Austria. Authors Triaki G, Souliotis K, Bouros...
by Symmetron | Jan 18, 2019
Idiopathic Pulmonary Fibrosis Cost-Effectiveness of Nintedanib in Idiopathic Pulmonary Fibrosis in the U.S. Presented at AMCP NEXUS. October 22-25, 2018. Orlando, USA Authors Rinciog C, Bermingham S, Cornic L, Diamantopoulos A, Fan YÂ Process \ Qualitative and...
by Symmetron | Jan 17, 2019
Idiopathic Pulmonary Fibrosis  A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK PharmacoEconomics. 2017 Apr;35(4):479-491 Authors Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A Process \ An...
Recent Comments